Non-Small Cell Lung Cancer Clinical Trial
Official title:
Combined Mindfulness-Based Stress Reduction and Exercise Intervention for Improving Psychological Well-being in Chinese Patients With Non-Small Cell Lung Cancer
NCT number | NCT06224504 |
Other study ID # | SBH-001 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 1, 2021 |
Est. completion date | January 1, 2024 |
Verified date | January 2024 |
Source | Shanxi Bethune Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study is to assess the clinical effectiveness of combining Mindfulness-Based Stress Reduction (MBSR) with exercise intervention in improving anxiety, depression, sleep quality, and mood regulation in Chinese patients with non-small cell lung cancer (NSCLC).The control group received conventional psychological nursing care, while the intervention group received a combination of MBSR and exercise therapy. Pre- and post-treatment scores of anxiety, depression, sleep quality, and the BSRS-5 were compared.
Status | Completed |
Enrollment | 60 |
Est. completion date | January 1, 2024 |
Est. primary completion date | January 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 44 Years to 65 Years |
Eligibility | Inclusion Criteria: - patients diagnosed with non-small cell lung cancer - patients aged between 20 and 74 years, without gender limitation - a score of 4-14 on the Short Symptom Rating Scale (BSRS-5) - a clinical prognosis of at least 6 months - clear consciousness, good functional ability, and unrestricted language communication - written informed consent provided by the patient Exclusion Criteria: - patients with severe physical illnesses or symptoms that impede learning and are considered life-threatening - patients with a BSRS-5 assessment score > 15 and suicidal ideation > 2 - patients unable to accurately describe their symptoms - patients with limited cooperation ability - patients who have previously undergone MBSR or other positive-thinking-focused psychotherapy methods |
Country | Name | City | State |
---|---|---|---|
China | Combined Mindfulness-Based Stress Reduction and Exercise Intervention for Improving Psychological Well-being in Chinese Patients with Non-Small Cell Lung Cancer | Taiyuan | Shanxi |
Lead Sponsor | Collaborator |
---|---|
Shanxi Bethune Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | SAS score | Self-Rating Anxiety Scale (SAS) | one day before the intervention | |
Primary | SAS score | Self-Rating Anxiety Scale (SAS) | at 6 weeks after the intervention | |
Primary | SAS score | Self-Rating Anxiety Scale (SAS) | at 8 weeks after the intervention | |
Primary | SDS score | Self-Rating Depression Scale (SDS) | one day before the intervention | |
Primary | SDS score | Self-Rating Depression Scale (SDS) | at 6 weeks after the intervention | |
Primary | SDS score | Self-Rating Depression Scale (SDS) | at 8 weeks after the intervention | |
Primary | BSRS-5 score | the five-item Brief Symptom Rating Scale (BSRS-5) | one day before the intervention | |
Primary | BSRS-5 score | the five-item Brief Symptom Rating Scale (BSRS-5) | at 6 weeks after the intervention | |
Primary | BSRS-5 score | the five-item Brief Symptom Rating Scale (BSRS-5) | at 8 weeks after the intervention | |
Primary | PSQI score | Pittsburgh Sleep Quality Index (PSQI) | one day before the intervention | |
Primary | PSQI score | Pittsburgh Sleep Quality Index (PSQI) | at 6 weeks after the intervention | |
Primary | PSQI score | Pittsburgh Sleep Quality Index (PSQI) | at 8 weeks after the intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |